Caldolor study was a double-blind, placebo-controlled malaria trial that evaluated 60 adults with acute uncomplicated falciparum malaria who were treated with artemisinin combination therapy.
In the study, patients who received IV Ibuprofen experienced a greater reduction in fever than those who received placebo during the first 24 hours, and on through 72 hours, following initial administration of study drug. The times for the mean temperature to fall below 37 degrees C were three hours for IV ibuprofen and 20 hours for placebo.
Cumberland Pharma’s new data support findings from other previously published studies on the effectiveness of Caldolor injection for the treatment of both fever and pain.
Kazimi, CEO of Cumberland Pharmaceuticals, said: “These findings validate our belief that Caldolor is a safe and effective way to reduce fever in patients suffering from a range of illnesses.
“We believe the data supporting the efficacy of IV Ibuprofen to reduce fever in critically ill malaria or sepsis patients offer support for its use in treating fever from a variety of sources, especially in patients who cannot tolerate oral medications.”